Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
SS Joshi, T Singh, DE Newby, J Singh - Heart, 2021 - heart.bmj.com
Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure
compared with the healthy population. In recent landmark clinical trials, sodium-glucose co …
compared with the healthy population. In recent landmark clinical trials, sodium-glucose co …
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado… - Journal of the American …, 2021 - jacc.org
Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF …
Background: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure–
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …
Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study
CG Santos-Gallego, JA Requena-Ibanez… - Cardiovascular …, 2021 - jacc.org
Objectives The purpose of this study was to investigate the effect of empagliflozin on
diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) …
diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) …
[HTML][HTML] SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of …
Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …
[HTML][HTML] SGLT2 inhibitors and their mode of action in heart failure—has the mystery been unravelled?
S Pabel, N Hamdani, M Luedde, S Sossalla - Current heart failure reports, 2021 - Springer
Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …
Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
N Zhang, Y Wang, G Tse… - European journal of …, 2021 - academic.oup.com
Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …